Loading
Latest filing published 18 Jun 2024 for Celldex Therapeutics, Inc., €290k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Elizabeth Crowley, listed as senior executive, appears in our data through filings on Celldex Therapeutics, Inc. shares, published by SEC (Form 4). We count 5 filings; the first trade dates from 1 November 2021 and the latest from 14 June 2024.
Not one of the filings records a straightforward purchase or sale on the market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
On 18 June 2024 came the latest disclosure, an option exercise for €290k in Celldex Therapeutics, Inc. Typically, a trade is published a median of 4 days after it takes place. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations